Trial Profile
A retrospective study to investigate PD-L1 heterogeneity and its impact on the predictive value on immune checkpoint inhibitor therapy in NSCLC patients-from GEMINI database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Brain metastases; Cancer metastases; Liver metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacodynamics; Therapeutic Use
- 08 Jun 2021 Results predicting clinical outcomes (progression free survival and overall survival) in patients with driver mutation NSCLC presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 14 May 2020 New trial record
- 07 May 2020 Results published in the Journal of Thoracic Oncology